Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...
Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...
The Print on MSN2d
Top pharma alliance refutes ‘ill-researched’ US study linking Indian generics to higher adverse eventsIndian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...
Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...
2don MSN
New Delhi, A trends study conducted by the federal financial intelligence unit of India has expressed "suspicion" that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback